Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Small Lymphocytic Lymphoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Non-Hodgkin’s Lymphoma (973
)
Diffuse Large B Cell Lymphoma (338
)
Mantle Cell Lymphoma (122
)
T Cell Non-Hodgkin Lymphoma (110
)
Follicular Lymphoma (82
)
Peripheral T-cell Lymphoma (65
)
Lymphoplasmacytic Lymphoma (63
)
Marginal Zone Lymphoma (37
)
Burkitt Lymphoma (20
)
Cutaneous T-cell Lymphoma (17
)
Mediastinal B Cell Lymphoma (10
)
Non-Hodgkin’s Lymphoma (973
)
Diffuse Large B Cell Lymphoma (338
)
Mantle Cell Lymphoma (122
)
T Cell Non-Hodgkin Lymphoma (110
)
Follicular Lymphoma (82
)
Peripheral T-cell Lymphoma (65
)
Lymphoplasmacytic Lymphoma (63
)
Marginal Zone Lymphoma (37
)
Burkitt Lymphoma (20
)
Cutaneous T-cell Lymphoma (17
)
Mediastinal B Cell Lymphoma (10
)
›
Associations
(102)
News
Trials
VERI cancer hierarchy
x
x
x
x
Reset Filters
No biomarker
Small Lymphocytic Lymphoma
No biomarker
Small Lymphocytic Lymphoma
acalabrutinib
Sensitive: A1 - Approval
AstraZeneca Press Release - 3 weeks (New A1)
acalabrutinib
Sensitive
:
A1
AstraZeneca Press Release - 3wk
acalabrutinib
Sensitive: A1 - Approval
AstraZeneca Press Release - 3 weeks
acalabrutinib
Sensitive
:
A1
AstraZeneca Press Release - 3 weeks - (New A1)
No biomarker
Small Lymphocytic Lymphoma
No biomarker
Small Lymphocytic Lymphoma
orelabrutinib
Sensitive: A1 - Approval
orelabrutinib
Sensitive
:
A1
orelabrutinib
Sensitive: A1 - Approval
orelabrutinib
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
No biomarker
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
No biomarker
Small Lymphocytic Lymphoma
ibrutinib + rituximab
Sensitive: A1 - Approval
ibrutinib + rituximab
Sensitive
:
A1
ibrutinib + rituximab
Sensitive: A1 - Approval
ibrutinib + rituximab
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
No biomarker
Small Lymphocytic Lymphoma
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
No biomarker
Small Lymphocytic Lymphoma
duvelisib
Sensitive: A1 - Approval
duvelisib
Sensitive
:
A1
duvelisib
Sensitive: A1 - Approval
duvelisib
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
No biomarker
Small Lymphocytic Lymphoma
ibrutinib
Sensitive: A1 - Approval
ibrutinib
Sensitive
:
A1
ibrutinib
Sensitive: A1 - Approval
ibrutinib
Sensitive
:
A1
CD20 positive
Small Lymphocytic Lymphoma
CD20 positive
Small Lymphocytic Lymphoma
obinutuzumab
Sensitive: A1 - Approval
obinutuzumab
Sensitive
:
A1
obinutuzumab
Sensitive: A1 - Approval
obinutuzumab
Sensitive
:
A1
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
PCR
Sensitive: A2 - Guideline
PCR
Sensitive
:
A2
PCR
Sensitive: A2 - Guideline
PCR
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
FCR
Sensitive: A2 - Guideline
FCR
Sensitive
:
A2
FCR
Sensitive: A2 - Guideline
FCR
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
alemtuzumab
Sensitive: A2 - Guideline
alemtuzumab
Sensitive
:
A2
alemtuzumab
Sensitive: A2 - Guideline
alemtuzumab
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
No biomarker
Small Lymphocytic Lymphoma
No biomarker
Small Lymphocytic Lymphoma
obinutuzumab
Sensitive: A2 - Guideline
obinutuzumab
Sensitive
:
A2
obinutuzumab
Sensitive: A2 - Guideline
obinutuzumab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
TP53 mutation
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
No biomarker
Small Lymphocytic Lymphoma
No biomarker
Small Lymphocytic Lymphoma
rituximab + idelalisib
Sensitive: A2 - Guideline
rituximab + idelalisib
Sensitive
:
A2
rituximab + idelalisib
Sensitive: A2 - Guideline
rituximab + idelalisib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
TP53 mutation
Small Lymphocytic Lymphoma
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
TP53 mutation
Small Lymphocytic Lymphoma
ibrutinib
Sensitive: A2 - Guideline
ibrutinib
Sensitive
:
A2
ibrutinib
Sensitive: A2 - Guideline
ibrutinib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
ibrutinib
Sensitive: A2 - Guideline
ibrutinib
Sensitive
:
A2
ibrutinib
Sensitive: A2 - Guideline
ibrutinib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
idelalisib
Sensitive: A2 - Guideline
idelalisib
Sensitive
:
A2
idelalisib
Sensitive: A2 - Guideline
idelalisib
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
TP53 mutation
Small Lymphocytic Lymphoma
idelalisib
Sensitive: A2 - Guideline
idelalisib
Sensitive
:
A2
idelalisib
Sensitive: A2 - Guideline
idelalisib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
TP53 mutation
Small Lymphocytic Lymphoma
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
rituximab + idelalisib
Sensitive: A2 - Guideline
rituximab + idelalisib
Sensitive
:
A2
rituximab + idelalisib
Sensitive: A2 - Guideline
rituximab + idelalisib
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
TP53 mutation
Small Lymphocytic Lymphoma
rituximab + idelalisib
Sensitive: A2 - Guideline
rituximab + idelalisib
Sensitive
:
A2
rituximab + idelalisib
Sensitive: A2 - Guideline
rituximab + idelalisib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
duvelisib
Sensitive: A2 - Guideline
duvelisib
Sensitive
:
A2
duvelisib
Sensitive: A2 - Guideline
duvelisib
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
TP53 mutation
Small Lymphocytic Lymphoma
duvelisib
Sensitive: A2 - Guideline
duvelisib
Sensitive
:
A2
duvelisib
Sensitive: A2 - Guideline
duvelisib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
venetoclax + rituximab
Sensitive: A2 - Guideline
venetoclax + rituximab
Sensitive
:
A2
venetoclax + rituximab
Sensitive: A2 - Guideline
venetoclax + rituximab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
TP53 mutation
Small Lymphocytic Lymphoma
venetoclax + rituximab
Sensitive: A2 - Guideline
venetoclax + rituximab
Sensitive
:
A2
venetoclax + rituximab
Sensitive: A2 - Guideline
venetoclax + rituximab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
TP53 mutation
Small Lymphocytic Lymphoma
obinutuzumab
Sensitive: A2 - Guideline
obinutuzumab
Sensitive
:
A2
obinutuzumab
Sensitive: A2 - Guideline
obinutuzumab
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
obinutuzumab
Sensitive: A2 - Guideline
obinutuzumab
Sensitive
:
A2
obinutuzumab
Sensitive: A2 - Guideline
obinutuzumab
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
alemtuzumab
Sensitive: A2 - Guideline
alemtuzumab
Sensitive
:
A2
alemtuzumab
Sensitive: A2 - Guideline
alemtuzumab
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login